Enjoy complimentary customisation on priority with our Enterprise License!
About RLS
RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.
Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1 Mirapex/Sifrol/Mirapexin
05.2 Requip
05.3 Neupro/Leganto
05.4 HORIZANT/Regnite
06. Introduction
07. Disease Overview
07.1 Understanding RLS
07.1.1 Types of RLS
07.2 Etiology and Pathogenesis
07.2.1 Genetic Factors
07.2.2 Iron Deficiency
07.2.3 Other Disease Conditions/Medications
07.2.4 Neurological Disturbances
07.3 Signs and Symptoms
07.4 Diagnosis
07.4.1 Differential Diagnosis of RLS
07.5 Management
07.5.1 Pharmacological Therapy
07.5.2 Non-pharmacological Therapy
07.6 Epidemiology
07.7 Economic Burden
08. Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 Injectafer
08.1.2 Lisuride
08.1.3 Incobotulinumtoxin A
08.1.4 IPX-159
08.1.5 Safinamide
08.1.6 AZ-008
08.1.7 SER-214
09. Commercial Opportunities
10. Key Brand Analysis
11. Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis
12. Market Segmentation by Class of Drugs
12.1 Dopaminergic Drugs
12.2 Opioids
12.3 Anticonvulsants
12.4 Sedatives and Hypnotics
12.5 Others
13. Geographical Segmentation
13.1 Global Restless Legs Syndrome Market by Geography 2014-2019
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 UCB
21.2.2 GlaxoSmithKline
21.2.3 Boehringer Ingelheim
21.2.4 XenoPort
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Boehringer Ingelheim
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Geographical Segmentation by Revenue 2013
22.1.6 Business Strategy
22.1.7 Recent Developments
22.1.8 SWOT Analysis
22.2 GlaxoSmithKline
22.2.1 Key facts
22.2.2 Business overview
22.2.3 Business segmentation by revenue 2014
22.2.4 Business segmentation by revenue 2013 and 2014
22.2.5 Geographical segmentation by revenue 2014
22.2.6 Business strategy
22.2.7 Recent developments
22.2.8 SWOT analysis
22.3 UCB
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Product Segmentation by Revenue 2013
22.3.4 Product Segmentation by Revenue 2012 and 2013
22.3.5 Geographical Segmentation by Revenue 2013
22.3.6 Business Strategy
22.3.7 Recent Developments
22.3.8 SWOT Analysis
22.4 XenoPort
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Strategy
22.4.4 SWOT Analysis
23. Other Reports in this Series
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.